- Featured Product
- KD/KO Validated
VSTM2L Polyclonal antibody
VSTM2L Polyclonal Antibody for IHC, ELISA
Host / Isotype
Rabbit / IgG
Reactivity
human
Applications
WB, IHC, ELISA
Conjugate
Unconjugated
Cat no : 25457-1-AP
Synonyms
Validation Data Gallery
Filter:
Tested Applications
| Positive IHC detected in | human liver tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
Recommended dilution
| Application | Dilution |
|---|---|
| Immunohistochemistry (IHC) | IHC : 1:50-1:500 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Published Applications
| KD/KO | See 1 publications below |
| WB | See 1 publications below |
Product Information
25457-1-AP targets VSTM2L in WB, IHC, ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Cited Reactivity | human |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen | VSTM2L fusion protein Ag22292 相同性解析による交差性が予測される生物種 |
| Full Name | V-set and transmembrane domain containing 2 like |
| Calculated molecular weight | 204 aa, 22 kDa |
| GenBank accession number | BC033818 |
| Gene symbol | VSTM2L |
| Gene ID (NCBI) | 128434 |
| RRID | AB_2880089 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
Protocols
| Product Specific Protocols | |
|---|---|
| IHC protocol for VSTM2L antibody 25457-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
| Species | Application | Title |
|---|---|---|
Biochem Biophys Res Commun VSTM2L contributes to anoikis resistance and acts as a novel biomarker for metastasis and clinical outcome in ovarian cancer
|
